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Abstract 
Introduction: Present study aimed to determine the frequency of invasive breast cancer (IBC) 
immunophenotypes in the General County Hospital Vinkovci, examine a difference between the ages 
of patients with respect to immunophenotypes and axillary lymph node (ALN) status, and determine 
differences in the frequency of positive ALNs with respect to immunophenotypes and the 
proliferation index (Ki67), regardless of the immunophenotype. 
Materials and Methods: A monocentre cross-sectional study which included 289 patients diagnosed 
with invasive breast cancer was conducted in the period from 1 January 2011 to 31 December 2018. 
The expression of IBC biomarkers was determined by immunohistochemistry. 
Results: The most common immunophenotype (41.54 %) was luminal B-like HER2-negative 
(LumB/HER2-). The mean age was 65.24 (± 12.04), with no age difference with respect to 
immunophenotypes (F = 0.64, P = 0.43) or ALN status (t = 1.59; P = 0.11). A total of 167 patients (58 %) 
had their ALNs removed, 66 % of which were positive. LumB/HER2- appeared to have significantly 
more positive ALNs compared to the luminal A-like immunophenotype (P < 0.01), while a difference 
in the size of primary tumours between metastatic breast cancers of these two immunophenotypes 
has not been detected (P = 0.17). ALNs were more likely to be positive in those tumours with Ki67 
values higher than 20 % compared to the tumours in which Ki67 was lower than or equal to 20 % (P < 
0.01). 
Conclusions: LumB/HER2- is the most prevalent IBC immunophenotype in patients in our institution 
and has significantly more positive ALNs compared to the luminal A-like immunophenotype. Also, 
metastases to ALNs, regardless of the immunophenotype, are more common in patients with Ki67 
higher than 20 % than in those with Ki67 lower than or equal to 20 %.. 
 
(Kovačević M, Švagelj I, Vučko M, Švagelj D. Differences in the Value of Proliferation Index (Ki67) and 
Immunophenotypes Between Invasive Breast Cancers With Respect to the Axillary Lymph Node 
Status. SEEMEDJ 2021; 5(1); 157-169) 
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Introduction 
Breast cancer is the most common malignancy 
in women in the European Union (1). Breast 
cancers are divided into non-invasive (in situ), 
microinvasive and invasive carcinomas with 
recognisable subtypes. Non-invasive 
carcinomas, unlike invasive carcinomas, do not 
have the ability to invade blood and lymphatic 
vessels and their tumour cells are limited to 
ducts. Non-invasive carcinomas include ductal 
carcinoma in situ (DCIS), intraductal papillary 
carcinoma, and lobular carcinoma in situ (LCIS) 
(2). Histologically, invasive carcinomas can be 
divided into ductal (80%) and lobular (10%), while 
the rest are special forms of breast cancer 
(Paget's disease of the nipple, colloid mucinous 
carcinoma, tubular carcinoma, and solid 
papillary carcinoma with invasion) (3). According 
to literature, different types of breast cancers 
originate from the luminal and basal cells of the 
terminal duct lobular unit epithelium and they 
form a heterogeneous group of cancers that 
cannot be distinguished by histology (4, 8).   
When it comes to breast cancer treatment, 
monitoring and survival rates, molecular 
subtypes determined by microarrays with more 
than 2.000 genes take precedence over the 
standard histological phenotype. This method is 
not easily attainable and it is quite costly, so it is 
generally accepted to use the 
immunophenotypic classification instead, as 
determined by the immunohistochemical 
expression of oestrogen receptors (ER), 
progesterone receptors (PR), proliferation index 
(Ki67) and amplification of the human epidermal 
growth factor receptor 2 (HER2) (2, 5). According 
to the new guidelines (Croatian Association for 
Cancer Research, 2018), ER and PR are 
considered weak prognostic and strong 
predictive factors because hormone receptor-
positive cancers have a better survival rate, 
since they predictively indicate a potential 
response to hormonal therapy (5-6). ER indicates 
a response to cancer treatment via hormonal 
therapy such as tamoxifen, which blocks the 
growth of oestrogen-stimulated cancers, and a 
response to aromatase inhibitors that suppress 
oestrogen production (5). The next 
immunophenotypic marker, HER2, is associated 
with a lower survival rate and is also a predictive 
factor. One of the main reasons for determining 
the HER2 status is the identification of 
candidates for targeted anti-HER2 therapy 
(trastuzumab, lapatinib, pertuzumab, and 
trastuzumab emtansine) related to HER2-
positive breast cancers. The most controversial 
marker used is Ki67, as it is determined in hot-
spot areas, and the result often depends on the 
quality of tissue fixation, formulation, and the 
type of antibody used (5). As a rule, a more 
distinct expression is associated with a lower 
survival rate, both in general and after the 
administration of neoadjuvant therapy (2, 5, 7, 8). 
In addition to being connected with 
immunophenotypes, the survival rate and 
treatment also depend on the penetration of 
malignant cells into blood and lymphatic 
vessels, tumour necrosis, age of the patient 
(younger age is a negative prognostic factor), 
size of the tumour, status of surgical margins and 
lymph nodes (2, 5). 
Studies from different countries show a different 
prevalence of respective immunophenotypes of 
breast cancer, which points not only to a number 
of factors that may play a role in carcinogenesis, 
but also to possible differences due to non-
standardised protocols in pathohistological 
laboratories. In addition, the diagnosis of the 
correct immunophenotype is the cornerstone of 
proper treatment. Therefore, it is necessary to 
evaluate one’s own work, among other things, 
comparing it with other laboratories in Croatia 
and other countries in order to detect possible 
problems in time and improve or at least 
maintain quality at an acceptable level. 
Therefore, the objective of this research was to 
determine the overall incidence of breast cancer 
and individual immunophenotypes in General 
County Hospital Vinkovci (CBC), to examine 
whether there is a difference between the age of 
women diagnosed with cancer related to 
immunophenotypes and lymph node status, and 
to determine the differences in the frequency of 
positive axillary lymph nodes with respect to 
immunophenotypes and especially with regard 
to high Ki67 values, regardless of the 
immunophenotype. 
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Materials and Methods  
Study Structure and Materials 
The paper is based on a monocentre cross-
sectional study on historical data (9). The 
findings of patients diagnosed with breast 
cancer in the period from 1 January 2011 to 31 
December 2018 were collected from the 
archives of the Department of Pathology and 
Cytology of the General County Hospital 
Vinkovci. From a total of 296 patients diagnosed 
with breast cancer, three were men, who were 
excluded from further processing. Also, because 
of the criteria of invasiveness, four female 
patients diagnosed with carcinoma in situ were 
excluded. Therefore, the final sample consisted 
of medical findings of 289 female patients with 
said diagnosis. The research was approved by 




Data of interest in the findings expressed ER, PR, 
HER2, and KI67 and were obtained using 
routinely prepared histological samples, 
formalin fixed paraffin embedded – FFPE, and 
finally immunohistochemically stained. The 
preparations were stained with Dako EnVision 
FLEX kit by treating the sample with Peroxidase 
Blocking Reagent (for 5 minutes), rinsed with 
EnVision FLEX wash buffer and treated with the 
primary antibody called FLEX Monoclonal 
Rabbit Anti-Human Estrogen receptor α, Clone 
EP1 (Dako), or other antibodies like Mouse Anti-
Human Progesterone Receptor, Clone PgR 636 
(Dako), FLEX Monoclonal Rabbit Anti-Human 
Ki67 Antigen, Clone MIB-1 (Dako) and 
Monoclonal Rabbit Anti-Human Her 2 Protein 
(Dako) (for 20 min), rinsed with EnVision FLEX 
wash buffer and stained with EnVision FLEX 
Hematoxylin. Finally, the preparations were 
covered with Sakura Tissue-Tek film in an 
automatic glass coating device Sakura Tissue-
Tek Film (10). Analysis and interpretation of the 
immunohistochemical staining findings were 
carried out according to the WHO guidelines (8). 
The ER and PR findings are considered positive 
if 1 % or more tumour cells show 
immunohistochemical nuclear positivity, and 
negative in case of absence of nuclear positivity 
or strong nuclear positivity in less than 1 % of 
total tumour tissue. If tumour cells show 
absence of membrane positivity or very weak 
membrane positivity to the HER2 antibody, the 
HER2 status is indicated with 0 or 1+ and the 
finding is considered negative. In contrast, if 
more than 10 % of tumour cells have membrane 
positivity, the finding is considered positive and 
marked with 3+. When tumour cells show 
incomplete membrane positivity in 10 % of 
tumour tissue or if the positivity is at the 
borderline of 10 % of the total tumour tissue, the 
HER2 status is denoted by 2+. In this case, 
additional in situ hybridisation (FISH/CISH) is 
required to determine the existence of 
amplification of the HER2 gene and categorise 
the tumour as HER2-positive or HER2-negative 
(8). 
According to immunohistochemically 
determined expression, we distinguish the 
following five immunophenotypes: luminal A-
like, luminal B-like HER2-negative, luminal B-like 
HER2-positive, HER2-positive and triple-
negative breast cancer (Table 1). Luminal A-like 
immunophenotype has the best survival rate, 
while a triple-negative immunophenotype has 
the worst survival rate (2). Luminal B-like HER2-
negative breast cancer immunophenotype 
should exhibit higher Ki67 values than luminal A-
like. Both immunophenotypes are HER2-
negative and ER-positive, but the luminal B-like 
HER2-negative immunophenotype has a lower 
survival rate, so the separation of these two 
breast cancer immunophenotypes is essential 
for therapy prescription. According to the 
recommendations of the St. Gallen Oncology 
Conferences from 2013 and the 2017 Croatian 
Guidelines for Quality Assurance in Breast 
Cancer Screening and Diagnosis, the cut-off 
value for this factor is 20 % (11-12). The cut-off 
value is important in clinical practice because it 
indicates which patients should receive a more 
intensive therapy (13). 
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Table 1. Immunophenotypes of breast cancer 
Immunophenotype ER PR Her2 Ki67 
Luminal A-like + + - < 20 % 
Luminal B-like HER2-
negative* 
+ -  
or low* 
- > 20 %* 
Luminal B-like HER2-
positive 
+ +/- + +/- 
HER2-positive - - + +/- 
Triple-negative - - - +/- 
*At least one of the following criteria is required 
 
After thorough processing, the pathohistological 
findings indicate tumour size, malignancy, Ki67, 
hormone receptor status, HER2 status, tumour-
to-resection-margin ratio, number of examined 
and positive axillary lymph nodes, and tumour-
to-blood and lymphatic vessel ratio. Finally, after 
processing these data according to the TNM 
staging system, the stage of breast cancer is 
determined indicating the probability of being 
cured (14). 
Statistical methods 
The variables were collected in MS Excel and 
processed in the program R (15). The sample was 
described using descriptive statistical methods. 
The Shapiro–Wilk W-test (or, in case of a large 
number of samples, the Kolmogorov–Smirnov 
test) was used to examine the distribution of 
numerical variables. A comparison of categorical 
variables was carried out using the Pearson's 
chi-squared test and the Fisher's exact test. 
ANOVA was used when comparing several 
groups of numerical variables, given the 
distribution of data was normal, and an adequate 
post-hoc test was used in cases of statistically 
significant results. The parametric Student’s t-
test was used to compare two groups of 
numerical variables with normal distribution. In 
this paper, the level of statistical significance for 




The research included 289 patients with breast 
cancer. The highest number of patients (45) was 
in 2018, and the lowest (26) in 2011 (χ2 = 5.09, P 
= 0.65). A difference was observed in the 
frequency of occurrence of certain 
immunophenotypes throughout the research 
period: the luminal B-like HER2-negative 
immunophenotype was more common in 2013 
than in other years (χ2 = 3.41, P = 0.03), while the 
luminal B-like HER2-positive immunophenotype 
was prevalent in 2017 (χ2 = 3.89, P < 0.01) (Figure 
1). According to the pathohistological diagnosis, 
the majority of patients (238) were diagnosed 
with invasive ductal carcinomas. Invasive lobular 
breast cancers were present in 30 patients and 
invasive mucinous carcinomas in 10. The rest of 
the patients had less common pathohistological 
types of breast cancer (Table 2). 
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Figure 1. Distribution of patients with breast cancer with regard to immunophenotypes by years 
during the research period 
Luminal B-like HER2-negative immunophenotype was more common in 2013 than in other years (*χ2 = 3.41, P = 0.03), 
while the luminal B-like HER2-positive immunophenotype was most common in 2017 (# χ2 = 3.89, P < 0.01). When it 
comes to other immunophenotypes, there was no difference in the frequency between the years within the research 
period (Figure 1). Index: lumA = luminal A-like; lumB = luminal B-like HER2-negative; lumB/Her2 = luminal B-like HER2-
positive; Her2 = HER2-positive, tr_neg = triple-negative 
 
Table 2. Pathohistological diagnosis of breast cancer (n (%)) 
Histological type of breast cancer Number (%) of patients 
Infiltrating duct carcinoma NOS 238 (82.3) 
Lobular carcinoma NOS 30 (10.4) 
Mucinous adenocarcinoma 10 (3.5) 
Solid papillary carcinoma with invasion 5 (1.7) 
Metaplastic carcinoma NOS 3 (1.0)  
Tubular carcinoma 2 (0.7) 
Apocrine adenocarcinoma 1 (0.4) 
Total 289 (100) 
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The mean age of the patients was 65.24 (95 % CI 
63.84 – 66.63). The sample follows the normal 
distribution (d = 0.05; P = 0.4). Regarding the 
immunophenotype of breast cancer, there was 
no difference in the age of the diseased patients 
(F = 0.64, P = 0.43) (Figure 2)..
 Figure 2. Age of patients with breast cancer with respect to immunophenotypes 
The Shapiro-Wilk test helped determine that the age of all patients with respect to the immunophenotypes was 
distributed according to the normal distribution. There was no difference in the age of patients with regard to the breast 
cancer immunophenotype (F = 0.47, P = 0.49). The red line indicates the mean age of all patients, which is 65.24 (Figure 
2). Index: lumA = luminal A-like; lumB = luminal B-like HER2-negative; lumB/Her2 = luminal B-like HER2-positive; Her2 = 
HER2-positive; tr_neg = triple-negative. 
 
Axillary resections were performed in our 
institution on a total of 167 (58 %) patients. Of 
these 167 patients, 111 (66 %) had positive axillary 
lymph nodes (proven metastases of cancer 
tissue), and 56 (34 %) had negative results. The 
difference between respective 
immunophenotypes was determined with 
regard to the presence of positive axillary lymph 
nodes. The luminal B-like HER2-negative 
immunophenotype has positive axillary lymph 
nodes significantly more frequently than the 
luminal A-like (P < 0.01) (Figure 3). However, no 
difference in the primary tumour size (relative to 
pT) was observed between these 
immunophenotypes with positive axillary lymph 
nodes (P = 0.17) (Table 3). Furthermore, no age 
difference was observed between patients with 
positive and those with negative axillary lymph 
nodes (t = 1.59; P = 0.11). Patients with a Ki67 value 
higher than 20 % were more likely to have 
positive axillary lymph nodes than those with a 
Ki67 value lower than or equal to 20 %, 
regardless of the immunophenotype (χ2 = 9.26, 
P < 0.01) (Figure 4)..
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 Figure 3. Incidence of positive axillary lymph nodes with respect to immunophenotypes of breast 
cancer 
A difference was observed between the immunophenotypes of breast cancer in the frequency of detected positive 
axillary lymph nodes (χ2 = 12.87, P < 0.05), and a post-hoc analysis found that the luminal B-like immunophenotype 
has positive axillary lymph nodes much more frequently compared to the luminal A-like immunophenotype (P < 0.01) 
(Figure 3). Index: lumA = luminal A-like; lumB = luminal B-like HER2-negative; lumB/Her2 = luminal B-like HER2-positive; 
Her2 = HER2 positive; tr_neg = triple-negative; ln+ = positive axillary lymph nodes; ln- = negative axillary lymph nodes. 
 
Figure 4. Number of patients with positive and negative axillary lymph nodes depending on the level 
of the proliferation index (Ki67) 
Positive axillary lymph nodes are more common in breast cancer patients with Ki67 higher than 20 % (Ki67 > 20%) 
compared to those with Ki67 lower than or equal to 20 % (Ki67 ≤ 20 %), regardless of the immunophenotype in question 
(χ2 = 9.26, P < 0.01) (Figure 4). Index: ln+ = positive axillary lymph nodes; ln- = negative axillary lymph nodes 
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Table 3. Primary tumour size in luminal A-like and luminal B-like HER2-negative carcinomas that 
have positive axillary lymph nodes. 
 Primary tumour size  
Immunophenotype pT1 pT2 pT3 pT4 Total 
Lum A 10 7 1 2 20 
Lum B/Her2- 17 26 10 2 55 
Total 27 33 11 4 75 
There was no difference in the size of the primary tumour between the luminal A-like and luminal B-like Her2-negative 
immunophenotypes of breast cancers with positive axillary lymph nodes (P = 0.17). Index: LumA = luminal A-like; 
lumB/Her2 = luminal B-like HER2-negative 
 
Discussion 
This research has shown that the luminal B-like 
HER2-negative immunophenotype is the most 
common immunophenotype of breast cancer in 
patients who have undergone surgery in our 
facility. In addition, positive axillary lymph nodes 
are more common in case of this 
immunophenotype than the luminal A-like 
immunophenotype, regardless of the size of the 
primary tumour. By way of explanation, due to 
the known correlation between tumour size and 
metastases of breast cancer to axillary lymph 
nodes (8), the observed difference in the 
incidence of metastatic breast cancers 
regarding these immunophenotypes was further 
analysed with respect to primary tumour size 
(pT). Although the difference in the size of the 
primary tumour subject to examination has not 
been confirmed, it should be emphasised that 
the possibility that this could be determined by 
research on a larger number of samples cannot 
be ruled out. Also, this paper indicates that 
metastases to axillary lymph nodes, regardless 
of the immunophenotype, are more common in 
patients with breast cancer with a Ki67 value 
higher than 20 % than in those with a Ki67 value 
lower than or equal to 20 %. The analysis of 289 
patients with breast cancer found that the most 
common histological type was invasive duct 
carcinoma (82.3 %), followed by invasive lobular 
carcinoma (10 %) and invasive mucinous 
carcinoma (3.5 %). The same order of histological 
subtypes can be found in studies conducted in 
Germany (16), Saudi Arabia (17), Pakistan (18) and 
Nigeria (19), while the invasive ductal type was 
slightly less common (59 %) in one Italian study, 
and it was followed by invasive lobular type with 
14 % (20). On the other hand, invasive ductal 
carcinoma is the most common in China (94 %), 
but it is followed by invasive mucinous 
carcinoma, with invasive lobular carcinoma in 
the last place (21).  
The mean age of the patients included in this 
research was 65.24 years, which is similar to the 
results in clinical hospital centres, general 
hospitals, clinics and polyclinics all across the 
Republic of Croatia (22), as well as Serbia (65.59 
± 10.17) (23). A slightly lower mean age (55-57) 
was detected in studies carried out in Germany 
(16), Japan (24) and Brazil (25), while the lowest 
mean age (43-48) was in Sweden (26), Nigeria 
(19) and Pakistan (18) (Table 3). The significantly 
lower age of breast cancer patients in Africa is 
explained by Nigerian authors by the thesis that 
breast cancer occurs up to 15 years earlier in 
black people (19). 
An almost equal representation of respective 
immunophenotypes as found in our sample was 
noted in another research conducted in Croatia 
(22), and in a country bordering Croatia – Serbia 
(27), but also in Sweden (26) (Table 4). The 
luminal A-like immunophenotype is most 
prevalent in certain European countries 
(Germany and Italy) (16, 20), Asia (China and 
Japan) (21, 24), as well as in Saudi Arabia and the 
United States (17, 28). It is interesting to single out 
countries such as Pakistan (18), Vietnam (26), and 
especially Nigeria (19), in which HER2-positive 
and triple-negative immunophenotypes that are 
more common in younger people, are more 
aggressive and have a lower survival rate, 
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prevail partially or predominantly (29). This is a 
possible explanation as to why these three 
countries also have slightly lower age statistics 
when it comes to patients with breast cancer 
(Table 4). In addition to the presence of said 
immunophenotypes, the age of patients is 
certainly affected by the implementation of 
prevention programs, which is evident in the 
example of Sweden, which, despite the 
distribution of immunophenotypes similar to that 
in our research, has a much lower median age. In 
Sweden, the age threshold of women included 
in the prevention program is 40, i.e. 10 years 
younger than in the Republic of Croatia, where 
the threshold is 50 (30, 12). The observed 
geographical grouping of certain 
immunophenotypes suggests that, in addition to 
genetic, a certain significant role in the 
carcinogenesis of breast cancer is also played 
by environmental factors, which should certainly 
be investigated in future research.  
When it comes to the frequency of positive 
axillary lymph nodes, results from our sample 
made it clear that the luminal B-like 
immunophenotype metastasises significantly 
more frequently to axillary lymph nodes 
compared to the luminal A-like 
immunophenotype. A group of authors from 
Serbia obtained similar results (27). Contrary to 
our result, the authors of studies from Italy (20) 
and Brazil (25) did not come across significant 
differences. However, it should be pointed out 
that a general limitation of these comparisons 
with other studies lies in the fact that few of them 
have used a slightly different methodology in 
the determining of breast cancer 
immunophenotypes (indicated in Table 4). Minor 
differences in the methodology of the first group 
of studies is a consequence of a change in the 
cut-off value of the proliferation index from 14% 
to 20%, accepted after the conclusions of the St. 
Gallen Oncology Conferences in 2013 (11). In our 
opinion, although these important differences in 
determining the proliferation index have a huge 
impact on the type of treatment of each 
individual patient with breast cancer, they have 
a minor effect on the total immunophenotype 
ratio because a small minority of cases could be 
reclassified into a different immunophenotype if 
another classification system (the same as in our 
study) was used. On the other hand, major 
differences in the methodology presented in the 
second group of studies are the result of a lack 
of use of the proliferation index, which can be 
seen from the absence of the luminal B-like 
HER2-negative immunophenotype category 
(Table 4). Therefore, the previously discussed 
comparison of our results with the results from 
these studies could be biased. 
Regardless of the immunophenotype, in our 
research, axillary lymph nodes were more 
frequently positive in those patients with a Ki67 
value higher than 20 %. A group of authors from 
Serbia obtained a similar result, indicating the 
connection between positive axillary lymph 
nodes and elevated Ki67, but, in contrast to our 
study, it had to do with tumours in which Ki67 
was higher than 14 % (27). In a research 
conducted in Turkey, it was found that patients 
with higher stages of positive lymph nodes (pN2 
and pN3) have a higher average level of Ki67 
expression than those with lower stages and 
negative lymph nodes (pN0 and pN1) (31). 
Contrary to these conclusions, a research in 
Ethiopia found that there was no difference in 
the level of the Ki67 proliferation index between 
breast cancers that have positive and negative 
axillary lymph nodes, regardless of whether all 
cancers were divided into three groups 
according to the Ki67 level (Ki67 < 15 %; 15 % < 
Ki67 < 30 %; Ki67 > 30 %) or the average level of 
the proliferation index (13). Since the level of the 
Ki67 proliferation index amounting to 20 % is the 
limit that groups certain breast cancers into 
luminal A-like and luminal B-like 
immunophenotypes, the result obtained 
indirectly confirms that the luminal B-like 
immunophenotype has a lower survival rate 
than the luminal A-like immunophenotype, 
which is consistent with the literature (11). 
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Germany 4102 57 44.7 31.8 6.2 5.0 12.3 (16)# 
Japan 363 56.7 30.6 26.2 19.0 11.3 12.9 (24)# 
Brazil 269 55.4 23.79 10 34.61 14.50 17.10 (25) # 
Serbia 108 61 25.92 47.22 19.44 1.85 5.55 (27) # 
Italy 1487 -* 34.09 25.21 11.49 10.15 19.03 (20) # 
China 3198 51 65.3 - 19.0 6.5 9.2 (21) § 
Saudi 
Arabia 
359 49.8 58.5 - 14.5 12.3 14.8 (17) § 
Nigeria 118 46.9 28.8 - 6.7 17.9 46.6 (19)§ 
Pakistan 285 43.3 21.05 - 48.77 18.4 11.22 (18) § 
USA 50 571 -* 72.7 - 10.3 4.6 12.2 (28) § 
Vietnam 237 47.7 10.6 33.5 23.0 19.3 13.6 (26) 
Sweden 237 51.3 31.6 41.3 8.9 7.6 10.6 (26) 
Croatia 1868 62.3 31.32 45.67 11.67 4.50 6.80 (22) 
Croatia 289 65.24 26.64 41.54 15.22 6.22 10.38 This research 
* The data on patients’ age are not expressed as mean or median. 
# cut-off value of proliferation index is 14% 
§ proliferation index was not used 
lumA = luminal A-like; lumB = luminal B-like HER2-negative; lumB/Her2 = luminal B-like HER2-positive; Her2 = HER2-
positive; tr_neg = triple negative 
 
However, it is important to point out one of the 
limitations of these comparisons. In clinical 
pathology, the above-mentioned 
immunohistochemical marker Ki67 is observed 
by a microscope, using a semiquantitative 
method, the interpretation of which is subject to 
numerous factors, such as the experience of the 
pathologist, quality of equipment, and quality of 
sample processing. Therefore, that may be the 
cause of interlaboratory discrepancies in the 
interpretation of samples, and therefore lead to 
different results.  
This paper has potentially useful clinical as well 
as public health implications. Primarily, this study 
describes the distribution and characteristics of 
breast cancer, which may be useful in planning, 
adjusting, and improving treatment options, but 
also in assessing the risk of disease recurrence 
and death depending on the immunophenotype 
of breast cancer. In addition, a slight but 
SEEMEDJ 2021, VOL 5, NO. 1 Proliferation Index (Ki67) and Immunophenotypes in Invasive Breast Cancer 
167 Southeastern European Medical Journal, 2021; 5(1) 
 
continuous increase in the number of diagnosed 
cancers during the research period, as well as 
the data on the age of patients, can serve as 
criteria in evaluating the preventive program for 
early detection of breast cancer and in planning 
further steps in its improvement. 
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